Remission of refractory Crohn's disease with anti-IL-12/23 therapy in a patient undergoing hemodialysis: A case report.
Crohn's disease
anti-IL-12/23
case report
hemodialysis
ustekinumab
Journal
Hemodialysis international. International Symposium on Home Hemodialysis
ISSN: 1542-4758
Titre abrégé: Hemodial Int
Pays: Canada
ID NLM: 101093910
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
17
05
2023
received:
04
01
2023
accepted:
30
05
2023
medline:
21
7
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Crohn's disease is a relapsing chronic inflammatory condition of the intestine with increasing prevalence around the world. Biologic therapies are currently widely used and have proved safe and effective in treating moderate to severe Crohn's disease. However, contemporary bibliography contains little information about the use of these drugs in patients with end-stage renal disease undergoing hemodialysis. Here we present a case of a 47-year-old female patient with treatment-refractory Crohn's disease on hemodialysis. In this patient, treatment with the anti-IL-12/23 receptor antibody ustekinumab was effective in inducing and maintaining remission while being safe in administering throughout hemodialysis.
Substances chimiques
Interleukin-12
187348-17-0
Ustekinumab
FU77B4U5Z0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
E41-E44Informations de copyright
© 2023 International Society for Hemodialysis.
Références
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014 Jan 7;20(1):91-9.
Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. Surg Clin. 2019;99:1051-62.
Dunleavy KA, Pardi DS. Biologics: how far can they go in Crohn's disease? Gastroenterol Rep. 2022 Jan;25:10.
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7-11.
Kusakari Y, Yamasaki K, Takahashi T, Tsuchiyama K, Shimada-Omori R, Nasu-Tamabuchi M, et al. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: a case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. J Dermatol. 2015 Jul 1;42(7):727-30.
Gisbert JP, Chaparro M. Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)? J Clin Med. 2021 Nov 15;10(22):5318.
Johnson AM, Barsky M, Ahmed W, Zullow S, Galati J, Jairath V, et al. The real-world effectiveness and safety of Ustekinumab in the treatment of Crohn's disease: results from the SUCCESS consortium. Am J Gastroenterol. 2022 Sep 30;118(2):317-328.
Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548-58.
Larquey M, Girard C, Sbidian E, Richard MA, Aubin F, Schmutz JL. Efficacy of biologics in psoriasis patients under hemodialysis. Eur J Dermatol. 2017;27:531-3.
Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. Population pharmacokinetics and exposure-response analyses of Ustekinumab in patients with moderately to severely active Crohn's disease. Clin Ther. 2022;44:1336-55.
Nimmannitya K, Tateishi C, Mizukami Y, Hamamoto K, Yamada S, Goto H, et al. Successful treatment with ustekinumab of psoriasis vulgaris in a patient undergoing hemodialysis. J Dermatol. 2016 Jan 1;43(1):92-4.
Umezawa Y, Hayashi M, Kikuchi S, Fukuchi O, Yanaba K, Ito T, et al. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. J Dermatol. 2015 Jul;42(7):731-4.
Unamuno Bustos B, Sánchez RB, Martínez VO, Carazo JLS. Efficacy and safety of ustekinumab in a patient with chronic renal failure on hemodialysis. Int J Dermatol. 2014 Apr;53(4):e299-301.
Larquey M, Poreaux C, Cuny JF, Barbaud A, Schmutz J l. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis. Eur J Dermatol. 2014 Sep;24(5):618-9.
Kurata I, Tsuboi H, Takahashi H, Abe S, Ebe H, Hagiwara S, et al. Successful treatment with infliximab for refractory uveitis in a hemodialysis patient with behçet's disease and a review of the literature for infliximab use in patients on hemodialysis. Intern Med. 2015;54(12):1553-7.